Cabozanitinib Shows Anti-Tumor Activity Beyond Clear-Cell Renal Cell Carcinoma
A recent study inThe Lancet Oncology suggests that the benefits of one tyrosine kinase inhibitor may extend to other subtypes of RCC. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Reimbursement decisions on drugs for renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2019 Category: Drugs & Pharmacology Source Type: news

Renal Cell Carcinoma: Diagnosis and Management Renal Cell Carcinoma: Diagnosis and Management
This brief paper summarizes key points in the diagnosis and management of renal cell carcinoma.American Family Physician (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 22, 2019 Category: Intensive Care Tags: Family Medicine/Primary Care Journal Article Source Type: news

Dr. Marc-Oliver Grimm provided an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session
In this article, Dr. Marc-Oliver Grimm provides an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session.03/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 18, 2019 Category: Urology & Nephrology Source Type: news

Extra Weight in Adolescence Tied to Later Risk for Renal Cancer
Among Swedish men, overweight or obesity during adolescence tied to higher risk for renal cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 16, 2019 Category: Cancer & Oncology Tags: Family Medicine, Nephrology, Nursing, Oncology, Pediatrics, Urology, Journal, Source Type: news

Extra Weight in Adolescence Tied to Later Risk for Renal Cancer
FRIDAY, March 15, 2019 -- Overweight and obesity in adolescence is associated with an increased risk for developing renal cell carcinoma (RCC) later in life, according to a study published online Feb. 20 in the International Journal of Cancer. Anna... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 15, 2019 Category: Pharmaceuticals Source Type: news

Cabozantinib Shows Promise in Non-Clear-Cell Kidney Cancer Cabozantinib Shows Promise in Non-Clear-Cell Kidney Cancer
Cabozantinib demonstrated promising anti-tumor activity in non-clear-cell renal cell carcinoma, a less common type of kidney cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 6, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Toxicity, Clinical Outcomes of Varying Cabozantinib Dosage in Metastatic RCC
While clinical outcomes may be comparable in patients with metastatic renal cell carcinoma (RCC) who are treated with full vs reduced dose of cabozantinib, reduced dose may not be associated with decreased adverse events.03/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 6, 2019 Category: Urology & Nephrology Source Type: news

JAVELIN Renal 101: Combination Therapy vs Standard of Care in Advanced RCC
Research presented at ASCO GU 2019 compared PFS with avelumab and axitinib vs sunitinib in patients with advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 6, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients
This study investigates its clinicopathologic characteristics and outcomes at a national level.03/05/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 5, 2019 Category: Urology & Nephrology Source Type: news

A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma
This study aims to investigate the gene expression changes in papillary renal cell carcinoma(pRCC) and screen several genes and associated pathways of papillary renal cell carcinoma progression.03/05/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 5, 2019 Category: Urology & Nephrology Source Type: news

Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses phase III findings on a comparison of tivozanib and sorafenib in patients with refractory advanced renal cell carcinoma03/04/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 4, 2019 Category: Urology & Nephrology Source Type: news

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses current models used to estimate the risk of recurrence of kidney cancer.02/27/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 27, 2019 Category: Urology & Nephrology Source Type: news

ASCO GU 2019: When to Obtain Genetic Testing for Syndromic Renal Cell Cancer
Dr. Brian Schuch weighs in on genetic testing for kidney cancer.02/26/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 26, 2019 Category: Urology & Nephrology Source Type: news

Top Medications Used to Treat Kidney (Renal Cell Cancer)
This article discusses the top medications used to treat kidney cancer.02/25/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 25, 2019 Category: Urology & Nephrology Source Type: news

Axitinib as an Adjuvant Treatment of Renal Cell Carcinoma Axitinib as an Adjuvant Treatment of Renal Cell Carcinoma
Does the VEGF inhibitor axitinib reduce risk of recurrence in patients with locoregional RCC post nephrectomy?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 25, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Being overweight in adolescence may increase kidney cancer risk later in life
(Wiley) Being overweight has been linked with a higher risk of developing a form of kidney cancer called renal cell carcinoma (RCC) among adults, but it's unclear if this risk is present during adolescence. In an International Journal of Cancer study of adolescents who were followed for 37 years, researchers observed a trend for higher RCC risk with increasing body mass index during adolescence, where one-unit increase in body mass index conferred a six percent increased risk of RCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2019 Category: Cancer & Oncology Source Type: news

Pembrolizumab Plus Axitinib a New Standard in Metastatic RCC Pembrolizumab Plus Axitinib a New Standard in Metastatic RCC
First-line treatment with the anti-PD-1 immunotherapy pembrolizumab plus the VEGF-targeted tyrosine-kinase inhibitor axitinib extended overall survival and progression-free survival in patients with clear-cell metastatic renal cell carcinoma (mRCC), compared with the current standard of care, sunitinib, in the phase 3 KEYNOTE-426 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 21, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non –clear cell renal cell carcinoma (RCC).02/20/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 20, 2019 Category: Urology & Nephrology Source Type: news

Combo Regimens Effective for Tx of Metastatic Renal Cell Cancer
Two large trials show benefits for pembrolizumab - axitinib and avelumab - axitinib versus sunitinib (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 20, 2019 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news

Combo Regimens Effective for Tx of Metastatic Renal Cell Cancer
WEDNESDAY, Feb. 20, 2019 -- For first-line therapy of metastatic renal cell carcinoma, pembrolizumab plus axitinib and avelumab plus axitinib both show improved survival versus sunitinib, according to two studies published online Feb. 16 in the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 20, 2019 Category: Pharmaceuticals Source Type: news

' Exciting Times' With Immunotherapy for Kidney Cancer'Exciting Times' With Immunotherapy for Kidney Cancer
New combinations with immunotherapy are going to change the standard of care in metastatic renal cell carcinoma, but questions remain, and there are technicalities to consider, according to some experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 19, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO GU 2019: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma: Results from KEYNOTE-427 Cohort B
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC.02/19/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2019 Category: Urology & Nephrology Source Type: news

ASCO GU 2019: Analysis of Overall Survival Based on Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma
During the Rapid Abstract Session on Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Duran presented on the analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).02/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 18, 2019 Category: Urology & Nephrology Source Type: news

ASCO GU 2019: Genetic Evolution of Metastatic Renal Cell Cancer
At ASCO GU in San Francisco, Dr. Samra Turajlic discussed the evolution of metastatic renal cell carcinoma.02/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 18, 2019 Category: Urology & Nephrology Source Type: news

Pembrolizumab Plus Axitinib vs Standard Treatment For mRCC
Treatment with pembrolizumab plus axitinib improved response and survival compared with sunitinib in patients with advanced, or metastatic clear-cell renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

New Standard of Care for Metastatic Renal Cell Carcinoma New Standard of Care for Metastatic Renal Cell Carcinoma
Combination treatment with pembrolizumab and axitinib significantly improved survival outcomes as compared with sunitinib.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer
Nephron-sparing surgery (NSS) remains gold standard for the treatment of localised renal cell cancer (RCC), even in the case of a normal contralateral kidney.02/08/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 8, 2019 Category: Urology & Nephrology Source Type: news

Comparative study of renal cell carcinoma in patients less than 40 years of age and older age patients: A retrospective single-center study
Renal cell carcinoma (RCC) is typically found in the older age group between 50 and 70 years of age. However, diagnosis of renal cancer is increasing more rapidly in patients less than 40 years if age compared to older age patients.02/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 6, 2019 Category: Urology & Nephrology Source Type: news

Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study
Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop.02/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 6, 2019 Category: Urology & Nephrology Source Type: news

First-Line TKIs Less Effective in Non-Clear-Cell Renal Cell Carcinoma
According to a study that was published in Urologic Oncology, patients with metastatic non-clear-cell renal cell carcinoma (nccRCC) have worse outcomes from first-line therapy with tyrosine kinase inhibitors (TKIs) than patients with metastatic clear-cell RCC (ccRCC).01/31/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 31, 2019 Category: Urology & Nephrology Source Type: news

Personalized Vaccine to be Tested in Patients with Kidney Cancer
Researchers at the Dana-Farber Cancer Institute are working to develop a vaccine for the treatment of renal cell cancer.01/30/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 30, 2019 Category: Urology & Nephrology Source Type: news

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial
Sunitinib is administered on a rigid schedule that may not be optimal for all patients. We hypothesised that toxicity-driven dose and schedule changes would optimise drug exposure and outcome for each patient.01/29/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 29, 2019 Category: Urology & Nephrology Source Type: news

Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer
This study evaluates whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC).01/29/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 29, 2019 Category: Urology & Nephrology Source Type: news

Obesity Factors May Increase Kidney Cancer Risk
According to recent research conducted by Spectrum Health, certain factors such as diastolic blood pressure and fasting insulin were found to be associated with renal cell carcinoma.01/28/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 28, 2019 Category: Urology & Nephrology Source Type: news

Cutaneous metastasis of renal cell carcinoma: Fine needle aspiration provides rapid diagnosis
The diagnosis of cutaneous metastasis of renal cell carcinoma is challenging in a young person in absence of a prior history of cancer. In such situation, fine needle aspiration alone as a minimally invasive procedure can provide rapid, accurate and cost effective diagnosis, even in case of unknown primary.01/23/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 23, 2019 Category: Urology & Nephrology Source Type: news

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma.01/23/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 23, 2019 Category: Urology & Nephrology Source Type: news

New study identifies specific obesity-related risk factors for kidney cancer
(Spectrum Health) A new study confirms the long-suspected role of obesity as a risk factor for developing renal cell carcinoma (RCC), a type of kidney cancer, and identifies several specific obesity-related factors. These factors include multiple measures of obesity, diastolic blood pressure and fasting insulin. In contrast, the study found little evidence for an association with RCC risk for systolic blood pressure, circulating lipids, diabetes or fasting glucose. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 17, 2019 Category: Cancer & Oncology Source Type: news

Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC
VEGF TKIs have long defined the frontline standard of care in metastatic renal cell carcinoma (mRCC), but several promising trials evaluating their use in combination with immunotherapy agents may redefine the frontline setting in this patient population.01/15/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2019 Category: Urology & Nephrology Source Type: news

European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Yesterday, Bristol-Myers Squibb announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ( “low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).01/15/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2019 Category: Urology & Nephrology Source Type: news

European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
Bristol-Myers Squibb Company (NYSE: BMY) announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ("low-dose") for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC). (Source: World Pharma News)
Source: World Pharma News - January 15, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Royal Jelly May Ease Adverse Effects of RCC Drug Therapy
Royal jelly, a substance secreted by worker honeybees that is the exclusive food for queen bees, may ease the adverse effects of tyrosine kinase inhibitor (TKI) therapy for advanced renal cell carcinoma (RCC).01/11/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 11, 2019 Category: Urology & Nephrology Source Type: news

Clinical Trials to Treat Kidney (Renal Cell) Cancer
Looking to enroll in a clinical trial? Check out this list from the National Cancer Institute.01/08/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 8, 2019 Category: Urology & Nephrology Source Type: news

Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma
This study discusses stereotactic radiosurgery for multiple brain metastases from renal-cell carcinoma.01/04/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 4, 2019 Category: Urology & Nephrology Source Type: news

Some RCC Risk Factors Can Be Modified
Obesity, hypertension and smoking are the three modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma, according to a new study that was done by the University of Texas Health Science Center and the South Texas Veterans Healthcare System.01/03/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 3, 2019 Category: Urology & Nephrology Source Type: news

Kidney Stones Up Kidney Cancer Risk
According to investigators, kidney stones are associated with an increased risk of papillary renal cell carcinoma (RCC) and upper tract urothelial carcinoma (UTUC).01/02/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 2, 2019 Category: Urology & Nephrology Source Type: news

Kidney Stones Tied to Increased Renal Cell Carcinoma Risk
Risk increased for papillary RCC but not clear - cell RCC; risk for upper tract urothelial carcinoma increased (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 2, 2019 Category: Cancer & Oncology Tags: Nephrology, Oncology, Journal, Source Type: news

Kidney Stones Tied to Increased Renal Cell Carcinoma Risk
WEDNESDAY, Jan. 2, 2019 -- Kidney stones are associated with an increased risk for renal cell carcinoma (RCC), specifically papillary RCC, and upper tract urothelial carcinoma (UTUC), according to a study published online Dec. 19 in the British... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 2, 2019 Category: Pharmaceuticals Source Type: news

Cabozantinib in Brain Metastases From Renal Cell Carcinoma Cabozantinib in Brain Metastases From Renal Cell Carcinoma
Is cabozantinib, a tyrosine kinase inhibitor recently approved for the treatment of metastatic renal cell carcinoma, effective for brain metastases which have been resistant to radiation?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Renal Cell Carcinoma | Medscape Renal Cell Carcinoma | Medscape
Review in-depth clinical information, latest medical news, and guidelines on renal cell carcinoma and kidney cancer. Review current articles about kidney cancer treatment and kidney cancer prognosis, especially for metastatic renal cell carcinoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news